Year: 2021

Conference Call and Webcast at 8:30 a.m. ET TodayData from multiple VB-111 clinical trials expected in 2022, including the progression free survival (PFS) co-primary endpoint from the Phase 3 OVAL study expected in the second half of 2022More than 85% of the planned 400 patients in the OVAL Phase 3 study evaluating VB-111 in platinum resistant ovarian cancer have been enrolled; remains on track to complete enrollment in the first quarter of 2022VB-601, a monoclonal antibody targeting monocytes for prevalent and chronic inflammatory disorders, expected to enter the clinic in the second half of 2022TEL AVIV, Israel and NEW YORK, Nov. 15, 2021 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq: VBLT), a clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune...

VANCOUVER, British Columbia, Nov. 15, 2021 (GLOBE NEWSWIRE) — Lithium Americas Corp. (TSX: LAC) (NYSE: LAC) (“Lithium Americas” or the “Company”) has reported unaudited financial and operating results for the third quarter ended September 30, 2021. HIGHLIGHTS Caucharí-OlarozConstruction activities at Caucharí-Olaroz continue to advance, targeting first production by mid-2022 on the initial 40,000 tonnes per annum (“tpa”) lithium carbonate equivalent (“LCE”) operation. As of September 30, 2021, $519 million has been spent or 81% of the $641 million budget, with the majority of remaining budget committed. Over 1,200 workers are on site, with over 97% of the total workforce having received at least their first COVID-19 vaccine dose and over 60% have received two doses. With all major equipment on site, focus is on construction of...

Reports Continued Growth in Revenues and Canadian Recreational Market Share TORONTO, Nov. 15, 2021 (GLOBE NEWSWIRE) — Auxly Cannabis Group Inc. (TSX – XLY) (OTCQX: CBWTF) (“Auxly” or the “Company“), a leading consumer packaged goods company in the cannabis products market, today released its financial results for the three and nine months ended September 30, 2021. These filings and additional information regarding Auxly are available for review on SEDAR at www.sedar.com. All amounts are Canadian dollars except common shares (“Shares”) and per Share amounts. Q3 2021 Highlights and Subsequent EventsTotal net revenues of $24.5 million for the three months ended September 30, 2021 improved by approximately 95% year over year and 17% sequentially. Adjusted EBITDA of negative $6.5 million, improved modestly...

Record Quarterly Revenue of $171.1 Million, an Increase of 49% Year-Over-Year All-Time High Production Output for the Month of October As Company Continues to Scale Production Across Three Continents Company Updates Fiscal Year 2021 Outlook MALMÖ, Sweden, Nov. 15, 2021 (GLOBE NEWSWIRE) — Oatly Group AB (Nasdaq: OTLY) (“Oatly” or the “Company”), the world’s original and largest oat drink company, today announced financial results for the third quarter and nine months ended September 30, 2021. Toni Petersson, Oatly’s CEO, commented, “Global consumer demand for our products continues to be strong and grow as we expand production and increasingly scale our operations. The robust third quarter revenue increase reflects broad-based growth across geographies and sales channels. We’re pleased with our ability to continue to be a leader...

CAMBRIDGE, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) — Pyxis Oncology, Inc. (Nasdaq: PYXS), a preclinical oncology company focused on developing next-generation therapeutics for difficult to treat cancers, today reported financial results for its third quarter ended September 30, 2021 and provided a business update. “Our initial public offering was a tremendous milestone for Pyxis, allowing us to debut as a public company with a strong balance sheet well positioned to advance our lead programs toward the clinic,” said Lara Sullivan, M.D., Chief Executive Officer of Pyxis. “We are on track to submit Investigational New Drug (IND) applications for PYX-201 and PYX-202 by mid-2022, and for PYX-203 by 2023. With the resources we now have in hand, we are also focused on fully leveraging our ADC technology platform and proprietary target...

BARRIE, Ontario, Nov. 15, 2021 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids today announced its financial results for the three and nine months ended September 30, 2021, a period of transition in establishing itself as an international pharmaceutical company specializing in cannabis. Q3 2021 Key HighlightsReceived North America’s sole Drug Establishment Licence (“DEL”) amongst cannabis companies, which will allow MediPharm to conduct pharmaceutical manufacturing and sale of Active Pharmaceutical Ingredients and Finished Dose Goods containing cannabis. MediPharm’s current and future domestic Canadian cannabis partners will benefit from the DEL as MediPharm can now provide them a conduit to pharmaceutical...

Increase of 40% in third quarter revenue to $20.0 million over the corresponding period in 2020 Increase of 112% in year-to-date revenue to $58.6 million over the corresponding period in 2020 Raising 2021 full year revenue guidance to $77-79 million Addition of 61 new customer accounts expands and diversifies customer base Expansion of leadership team with senior life science executives Substantial cash and investments of $676 million enabling continued growth acceleration initiatives Company to host conference call today at 8:00 a.m. ETBOULDER, Colo., Nov. 15, 2021 (GLOBE NEWSWIRE) — SomaLogic, Inc., a leader in AI-data driven proteomics technology, today reported financial results for the quarter ended September 30, 2021. “I am pleased to announce third quarter results that exceeded our expectations and complement our growing...